TY - JOUR
T1 - Ipilimumab-induced immunomediated adverse events
T2 - possible pitfalls in (18)F-FDG PET/CT interpretation
AU - Gilardi, Laura
AU - Colandrea, Marzia
AU - Vassallo, Stefano
AU - Travaini, Laura L avinia
AU - Paganelli, Giovanni
PY - 2014/5/1
Y1 - 2014/5/1
N2 - A 42-year-old woman underwent resection of a high-risk melanoma of the right thigh. Adjuvant treatment with ipilimumab was then started within a phase III randomised, double-blind clinical trial. F-FDG PET/CT scan showed intense uptake in mediastinal hilar lymph nodes, bilaterally, and in rectus abdominis muscle. Biopsy at the abdominal wall revealed a chronic granulomatous inflammation. After oral steroid treatment, all the areas of abnormal tracer uptake disappeared. Ipilimumab can induce inflammatory immunomediated reactions that should be taken into account to avoid misinterpretation.
AB - A 42-year-old woman underwent resection of a high-risk melanoma of the right thigh. Adjuvant treatment with ipilimumab was then started within a phase III randomised, double-blind clinical trial. F-FDG PET/CT scan showed intense uptake in mediastinal hilar lymph nodes, bilaterally, and in rectus abdominis muscle. Biopsy at the abdominal wall revealed a chronic granulomatous inflammation. After oral steroid treatment, all the areas of abnormal tracer uptake disappeared. Ipilimumab can induce inflammatory immunomediated reactions that should be taken into account to avoid misinterpretation.
UR - http://www.scopus.com/inward/record.url?scp=84921425084&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84921425084&partnerID=8YFLogxK
U2 - 10.1097/RLU.0b013e31828da691
DO - 10.1097/RLU.0b013e31828da691
M3 - Article
C2 - 23640225
AN - SCOPUS:84921425084
SN - 0363-9762
VL - 39
SP - 472
EP - 474
JO - Clinical Nuclear Medicine
JF - Clinical Nuclear Medicine
IS - 5
ER -